semaglutide and prolactinoma – My Endo Consult Clinical consequences of prolactinoma include

Data suggest that semaglutide may lower the 10-year risk of developing type 2 diabetes by as much as 60% in people with overweight and weight-related complications or with obesity while on treatment

Tizaro is a dual GIP and GLP-1 receptor agonist

2 $3.2M Product Liability Settlement A resolution between disputing parties about a legal case, typically reached before court action begins

A few small human studies suggest possible skin benefits, but sample sizes were modest and long-term safety data are absent

Semaglutide Safety During Breastfeeding Current clinical evidence and manufacturer guidance indicate that semaglutide should be avoided during breastfeeding due to insufficient safety data in nursing mothers and infants